BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 10502826)

  • 1. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.
    Fabre JE; Nguyen M; Latour A; Keifer JA; Audoly LP; Coffman TM; Koller BH
    Nat Med; 1999 Oct; 5(10):1199-202. PubMed ID: 10502826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
    Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study.
    Braun OO; Jagroop A; Wang L; Mikhailidis DP; Burnstock G; Erlinge D
    Platelets; 2005 Aug; 16(5):261-7. PubMed ID: 16011976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
    Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
    J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P2Y1 receptor is essential for ADP-induced shape change and aggregation in mouse platelets.
    Kim YB; Jin J; Dangelmaier C; Daniel JL; Kunapuli SP
    Platelets; 1999; 10(6):399-406. PubMed ID: 16801119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADP-induced platelet activation.
    Puri RN; Colman RW
    Crit Rev Biochem Mol Biol; 1997; 32(6):437-502. PubMed ID: 9444477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation.
    Léon C; Vial C; Gachet C; Ohlmann P; Hechler B; Cazenave JP; Lecchi A; Cattaneo M
    Thromb Haemost; 1999 May; 81(5):775-81. PubMed ID: 10365753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation.
    Eckly A; Gendrault JL; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2001 Apr; 85(4):694-701. PubMed ID: 11341507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.
    Jantzen HM; Gousset L; Bhaskar V; Vincent D; Tai A; Reynolds EE; Conley PB
    Thromb Haemost; 1999 Jan; 81(1):111-7. PubMed ID: 10348701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
    Rozalski M; Nocun M; Watala C
    Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
    Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
    Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
    Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
    J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of intracellular signaling events in ADP-induced platelet aggregation.
    Daniel JL; Dangelmaier C; Jin J; Kim YB; Kunapuli SP
    Thromb Haemost; 1999 Oct; 82(4):1322-6. PubMed ID: 10544922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice.
    Hechler B; Zhang Y; Eckly A; Cazenave JP; Gachet C; Ravid K
    J Thromb Haemost; 2003 Jan; 1(1):155-63. PubMed ID: 12871553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.
    Hetherington SL; Singh RK; Lodwick D; Thompson JR; Goodall AH; Samani NJ
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):252-7. PubMed ID: 15514209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF; May JA; Heptinstall S
    Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.